SOLACE

Lung cancer is the second most diagnosed cancer among males and the third among females in EU member states and the leading cause of cancer death in both sexes. Several randomised trials from US and Europe have demonstrated the capability of low dose computed tomography (LDCT) to detect lung cancer early and significantly reduce mortality.

SOLACE (Strengthening the Screening of Lung Cancer in Europe) is an EU project funded under the EU4Health Programme 2021–2027. The aim of the project is to create clear, concise and practical guidelines on implementing a lung cancer screening programme at a national level.

The project will run pilots that will identify and enrol specific populations that are currently underrepresented or at higher risk of lung cancer. This includes women, people living with other diseases, ethnic minorities, people living in geographically remote regions, socially deprived populations and people living in remote areas.

More information is available at solacelung.eu.

Funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or European Health and Digital Executive Agency (HADEA). Neither the European Union nor the granting authority can be held responsible for them.

This project is co-funded under the EU4Health Programme 2021–2027 under grant agreement no. 101101187.